Document is current
Any future updates will be listed below
-
Authors
Alqarihi, Abdullah
Singh, Shakti https://orcid.org/0000-0001-6521-0998
Edwards, John E. Jr.
Ibrahim, Ashraf S.
Uppuluri, Priya
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01 AI063382, R01 AI063382)
- License Information
-
More Information
Article History
Received: 4 October 2018
Accepted: 29 March 2019
First Online: 17 April 2019
Competing Interests
: J.E.E. and A.S.I. are founders and shareholders of NovaDigm Therapeutics Inc. a company that is developing the NDV-3A as a fungal vaccine. All other co-authors have no formal association with NovaDigm.
